Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Skye Bioscience Inc
(OP:
SKYE
)
N/A
UNCHANGED
Last Price
Updated: 3:57 PM EDT, Apr 10, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Skye Bioscience Inc
< Previous
1
2
Next >
Key Marijuana Executive Changes: Who Will Lead MariMed After CEO's Passing? MJBiz CEO Steps Down
December 19, 2022
MJBiz CEO To Step Down Marijuana Business Daily's Chris Walsh will step down as CEO in January.
Via
Benzinga
Skye Initiates First-in-Human Phase 1 Clinical Trial For Cannabinoid Based Drug For Treatment Of Glaucoma
November 16, 2022
Skye Bioscience, Inc. (OTCQB: SKYE), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, has initiated screening for its first-in-human Phase 1 trial...
Via
Benzinga
Skye One Step Closer To Initiating Clinical Study Of Its Cannabinoid Based Drug For Treatment Of Glaucoma
September 20, 2022
Skye Bioscience, Inc. (OTCQB: SKYE), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, has been advised by its contract manufacturer that it has...
Via
Benzinga
Easy On The Eyes — This Company Reports Using a Unique Synthetic Cannabinoid Derivative To Treat Glaucoma
July 25, 2022
Modern cannabis research reportedly began with Israeli scientists Raphael Mechoulam and Yechiel Gaoni who, in 1964, isolated and identified tetrahydrocannabinol (THC). Mechoulam later also elucidated...
Via
Benzinga
Skye Bioscience Selects NextPharma As Phase 2 Contract Drug Manufacturer
July 21, 2022
Skye Bioscience, Inc. (OTCQB: SKYE) , a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, has selected NextPharma as its contract manufacturing...
Via
Benzinga
Skye Bioscience Targets Unmet Needs Of Glaucoma Through Cannabinoids
April 08, 2021
Skye Bioscience Inc. was a sponsor at the Benzinga Cannabis Capital Conference on February 25-26, 2021. The information contained in this artic...
Via
Benzinga
Topics
Cannabis
Exposures
Cannabis
Skye Bioscience Signs Arrangement Agreement With Emerald Health Therapeutics, Here Are The Details
May 12, 2022
Skye Bioscience, Inc. (OTCQB: SKYE) and Emerald Health Therapeutics, Inc.
Via
Benzinga
Skye Bioscience Shares Up On Keeping Novotech As CRO For Phase 1 Trial Of THC Prodrug Candidate For Glaucoma
March 03, 2022
Skye Bioscience, Inc. (OTCQB:SKYE) has entered into...
Via
Benzinga
Cannabis Movers & Shakers: Skye Bioscience, The Flowr Corp, Charlotte's Web, Rapid Dose Therapeutics
December 23, 2021
Skye Bioscience Announces Board Additions & Promotions CBD-focused biopharmaceutical company Skye Bioscience, Inc.
Via
Benzinga
These OTC Securities Had the Most Trading Activity in June
July 20, 2021
Photo by Cris Ovalle on Unsplash OTC Markets trading volume was still led by cryptocurrencies and cannabis for the month of June, but many other securities shined comparatively as...
Via
Benzinga
Topics
Cannabis
Exposures
Cannabis
Watch CV Sciences & Lyphe Group On The Benzinga Cannabis Hour
July 08, 2021
Benzinga’s Cannabis Hour is a live show for cannabis investors. On Thursday’s show, hosts Elliot Lane...
Via
Benzinga
Topics
Cannabis
Exposures
Cannabis
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.